medigraphic.com
ISSN 1561-3186 (Electronic)

2022, Number 4

<< Back Next >>

Rev Acta Médica 2022; 23 (4)

Control of comorbidities as a fundamental pillar during the COVID-19 pandemic

Yanes QMA, Yanes QM, Calderín BRO, Rodríguez BJA

Language: Spanish
References: 27
Page:
PDF size: 178.60 Kb.


ABSTRACT

Introduction: COVID-19 is an infectious disease caused by the SAR-COV-2 virus. People with advanced age, suffering from chronic diseases, especially with poor control such as arterial hypertension, type 2 diabetes mellitus, obesity and insulin resistance syndrome, among others, have a worse prognosis in the course of the infectious disease.
Objective: To argue the importance of controlling diabetes mellitus and its comorbidities from a stage prior to the possible infection by SAR-COV-2.
Methods: A bibliographic review on the updated topic (COVID-19 and diabetes mellitus) was carried out. After studying the most complete and updated references, the present study was carried out.
Conclusions: The accurate and timely diagnosis of comorbidities such as obesity and type 2 diabetes prior to a possible infection by COVID-19 is of great importance in order to improve the prognosis of patients.


REFERENCES

  1. Hernández J, Prieto R, Ríos G, Lledó G, Araujo O, Espígol G, et al. Respuesta inmunoinflamatoria en la COVID-19. En: Cervera R, Espinosa G, Ramos M, Hernández J, Prieto S, Espígol G. Enfermedades Autoinmunes Sistémicas. 6ta ed. Barcelona: Editorial Médica Panamericana; 2020. pp. 1-17.

  2. Reyes E. Inmunopatogenia en la evolución del paciente grave por la COVID-19. Rev Elect Dr. “Zoilo E. Marinello Vidaurreta”. 2020 [acceso: 15/12/2022];45(3):45-7. Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/2274

  3. Gómez J, Hernández C, Aguilera Y. Afectación del sistema cardiovascular en la infección por SARS-CoV-2. Univ Med Pinar Río. 2020 [acceso: 15/12/2022];16(3):521-3. Disponible en: http://www.revgaleno.sld.cu/index.php/ump/article/view/

  4. Vázquez LA, Miguel M, Machado MA, Torres L, Álvarez LM, Pantoja A. Vulnerabilidad ante la COVID-19 en adultos mayores con enfermedad cardiovascular. Univ Med Pinar Río. 2021 [acceso: 15/12/2022];17(1):601. Disponible en: www.revgaleno.sld.cu/index.php/ump/article/view/601

  5. Marsán V, Casado I, Hernández E. Respuesta inmune adaptativa en la infección por SARS-CoV-2. Rev Cubana Hematol, Inmunol y Hemoterap. 2020 [acceso: 15/12/2022]; 36. Disponible en: https://revhematologia.sld.cu/index.php/hih/article/view/1313

  6. Di Fabio J, Gofin R, Gofín J. Análisis del sistema de salud cubano y del modelo de atención primaria orientada a la comunidad. Rev Cubana Salud Pública. 2020 [acceso: 15/12/2022];46(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662020000200004&lng=es&nrm=iso>

  7. Rodríguez M. Factores de riesgo asociados a la mortalidad en pacientes adultos con neumonía por SARS-CoV-2 en un hospital público de Lima, Perú. Acta Med Perú. 2020;37(4):437- 46. DOI: http://dx.doi.org/10.35663/amp.2020.374.1676

  8. Hoffmann M, Kleine H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80. DOI: https://doi.org/10.1016/j.cell.2020.02.052

  9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;11. Disponible en: https://doi.org/10.1016/S2213-2600(20)30116-8

  10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;28(395):1014-5. DOI: https://doi.org/10.1016/S0140-6736(20)30633-4

  11. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. DOI: https://doi.org/10.1056/NEJMoa2002032

  12. García ME, Bell J, Romero D, Ferrales N. La COVID-19 en personas hipertensas. MEDISAN. 2020 [acceso: 15/12/2022];24(3):501-14. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192020000300501&lng=es

  13. Rao S, Lau A, So HC. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits. Diabetes Care. 2020;43(7):1416-26. DOI: https://doi.org/10.2337/dc20-0643

  14. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. DOI: https://doi.org/10.1111/j.1365-2249.2004.02415.x

  15. Lu R, Zhao X, Li J, Niu P, Yan B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;22(395):565-74. DOI: https://doi.org/10.1016/S0140-6736(20)30251-8

  16. Du RH, Liang RH, Yang CQ, Wang W, Chao TZ, Li M, et al. Predictor of mortality for patients with COVID-19 pneumonia caused by SARS-Cov-2. A prospective cohort. Eur Respir J. 2020;55(6):53-7. DOI: https://doi.org/10.1183/13993003.00524-2020

  17. Lai C, Liu YH, Wang C, Wang Y, Hsueh SY. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory sindrome coronavirus SARS-CoV-2: Facts and myths. J Microbiol Immunol Infec. 2020. DOI: https://doi.org/10.1016/j.jmii.2020.02.012

  18. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. DOI: https://doi.org/10.1001/jamainternmed.2020.099

  19. Gila R, Bitarb P, Dezaa C, Dreysea J, Matías C, Ibarraa J, et al. Cuadro Clínico del COVID-19. Rev Med Clin. CONDES. 2021;32(1):20-9. DOI: https://doi.org/10.1016/j.rmclc.2020.11.004

  20. Marhl M, Grubelnik V, Magdič M, Markovič R. Diabetes and metabolic syndrome as risk factors for COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):671-7. DOI: https://doi.org/10.1016%2fj.dsx.2020.05.013

  21. González R, Acosta F, Oliva E, Rodríguez S, Cabeza I. Diabetes, hiperglucemia y evolución de pacientes con la COVID-19. Rev Cubana Med Mil. 2021 [acceso: 15/12/2022];50(2). Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/960

  22. Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. Diabetes Obes Metab. 2020;22(8):1443-54. DOI: https://doi.org/10.1111/dom.14086

  23. Li B, Yang I, Zhao F, Zhi I, Whanf X, Liu L, et al. Prevalence and impact of cardiovacular metabolic disease on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. DOI: https://doi.org/10.1007/s00392-020-01626-9

  24. Rico J, Daza N, Pajaro N, Leal V, Abuabara E, Saenz J, et al. Obesidad y COVID-19. Archiv Med. 2020;16(4.3):3823-43. DOI: https://doi.org/10.3823/1443

  25. Gao F, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. DOI: https://doi.org/10.1016/j.

  26. Fernández G, Romero T, Troya E, Arráiz de Fernández C. La Adiponectina, una adipocina del tejido adiposo clave en la obesidad durante la adolescencia. Enfermería Investiga. 2016 [acceso: 15/12/2022];1(4)169-75. Disponible en: https://revistas.uta.edu.ec/erevista/index.php/enfi/article/view/775

  27. Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring). 2020;28(6):1005. DOI: https://doi.org/10.1002/oby.22818




2020     |     www.medigraphic.com